Andrea Schlegel, MD, MBA

• Dr. Schlegel obtained her medical degree with Honors from the Justus-Liebig-University Giessen (Germany). She completed her research fellowship and residency at the University Hospital Zurich (Switzerland), where she also served as Chief Resident and Staff Surgeon with a focus on quality improvement and patient safety in abdominal surgery and transplantation. She went on to complete her Transplant Surgery and Hepato-Pancreatico-Biliary Surgery fellowship training at Queen Elizabeth University Hospital Birmingham (United Kingdom) and was awarded with a Staff position as Transplant Surgeon before moving to Italy (Careggi Hospital Florence and Milan Policlinico), where she achieved the “National Scientific Qualification” as Full Professor (06/C1 - General Surgery). 
• Since 2011 her research is focused on a broad range of topics including dynamic organ preservation in context of transplantation, the development of new markers to predict organ viability, and underlying mechanisms of ischemia and reperfusion injury triggered by mitochondrial injury and dysfunction.
• Dr. Schlegel serves as Associated Editor and Reviewer in more than 15 leading journals in the field of surgery and organ transplantation and has various international collaborations worldwide with an average number of 20 invited lectures and presentations per year.
• Dr. Schlegel is board certified in General Surgery (FMH), Transplant Surgery (EBSQ/UEMS) and Hepato-Pancreatico-Biliary Surgery (EBSQ/UEMS) and obtained a Master in Business Administration (MBA, specialized in International Healthcare Management) from the Robert Kennedy College and University of Cumbria (United Kingdom and Switzerland).

• Certifications
• General Surgery
• Transplant Surgery
• Hepato-Pancreatico-Biliary Surgery

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-06-13, Dr. Schlegel has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Schlegel receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Bridge to Life, LTD

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.